腺病毒疫苗市場報告：2030 年趨勢、預測與競爭分析

腺病毒疫苗趨勢與預測

預計到 2030 年，全球腺病毒疫苗市場將達到 14 億美元，2024 年至 2030 年複合年成長率為 7.5%。該市場的主要促進因素是癌症基因療法疫苗接種需求的激增以及製藥公司疫苗接種需求的激增。全球腺病毒疫苗市場的未來看起來充滿希望，研究/學術、實驗室和製藥/生物技術市場存在機會。

Lucintel 預測，7 型疫苗預計將在預測期內出現強勁成長，因為它們價格實惠且能提供即時免疫力。

由於腺病毒感染的高流行和人口的持續成長，預計北美在預測期內將經歷最高的成長。

腺病毒疫苗市場的新趨勢

腺病毒疫苗市場正在透過各種新興趨勢不斷發展，成為創新和市場成長的關鍵驅動力。這些趨勢反映了疫苗技術的不斷發現和世界對抗感染疾病的鬥爭。

• 下一代疫苗：下一代腺病毒疫苗的開發旨在提高功效、安全性和遞送能力。這可以從基於載體的疫苗和旨在增強免疫反應同時減少副作用和其他副作用的新穎配方等創新中看到。
• 疫苗產能擴張：全球疫苗產能擴張趨勢明顯。為了確保腺病毒疫苗的穩定供應，特別是在 COVID-19 大流行期間，各國正在投資先進的生產設施。
• 全球疫苗分配：正在努力向低收入和中等收入國家提供腺病毒疫苗，並實現公平的全球疫苗分配。政府、非政府組織和製藥公司之間的夥伴關係是實現廣泛獲取的趨勢之一。
• 監管改革：監管機構正在迅速實施更靈活的腺病毒疫苗核准程序。這反映了公共衛生危機的緊迫性以及製造商將新藥迅速推向市場的需要。
• 研發合作：腺病毒疫苗市場的主要趨勢之一是研究機構、生技公司和政府之間加強合作。此類夥伴關係正在引領創新並加快疫苗開發的步伐。

這些趨勢正在透過推動創新、擴大生產能力和確保全球疫苗可及性來重塑腺病毒疫苗市場。為了應對新出現的感染疾病和公共衛生需求，市場正在迅速變化。

腺病毒疫苗市場近期趨勢

腺病毒疫苗市場的最新發展集中在全球公共衛生需求驅動的研究、貿易和供應方面的顯著進展。

• 擴大生產能力：領先的疫苗製造商正在提高生產能力，以滿足全球對腺病毒疫苗不斷成長的需求。此次擴建包括新設施和現有設施的改進，以增加產量並確保疫苗的供應。
• 政府資助和支持：世界各國政府正在投入巨額資金用於腺病毒疫苗的開發。此類財政支持可以採取多種形式，包括津貼、補貼或加速監管核准，以幫助疫苗快速成長。
• 合作研究計畫：與製藥公司的夥伴關係也正在推動腺病毒疫苗開發領域的創新。這些夥伴關係旨在提高疫苗的效率、管理和可近性。
• 全球經銷夥伴：公司正在建立合作夥伴關係，以促進這種疫苗的全球供應，特別是在低收入和中等收入國家。這些舉措的具體目的是縮小公平差距，並為最需要的人提供疫苗。

這些進步顯著改善了腺病毒疫苗產業，並實現了疫苗的有效生產、開發和交付，以應對全球公共衛生挑戰。

腺病毒疫苗市場的策略性成長機會

在技​​術進步和全球需求不斷成長的推動下，腺病毒疫苗市場在各種應用中存在一些策略性成長機會。

• 兒童疫苗接種計劃 加強兒童疫苗接種計劃將是成長的重要槓桿。這需要開發兒科專用腺病毒疫苗並將其納入國家免疫計劃，以滿足重要的兒童安全要求。
• 旅行和軍事疫苗接種：針對旅行者和軍事相關人員接種腺病毒疫苗是一項可以帶來持續成長的策略。由於這些人群更容易感染腺病毒，因此可以專門針對他們配製疫苗。
• 疫苗組合策略：將腺病毒疫苗與其他疫苗組合成單一劑量代表未來成長的機會。特別是在資源有限的環境中，這種免疫方法可以簡化時間表並增加覆蓋範圍。
• 流行病對策：預計未來腺病毒疫苗在流行病對策中的使用將會增加。為了全球衛生安全，需要儲備疫苗並在疫情爆發時迅速部署。
• 個人化疫苗：基於腺病毒開發與個人基因譜相符的個人化疫苗是業務擴張的新來源。希望將免疫反應與每個人的基因相匹配將提高疫苗的有效性。

這些成長策略正在支持腺病毒疫苗市場的開拓和擴大。專注於市場的關鍵應用可能會產生滿足關鍵公共衛生需求的解決方案，類似於全球疫苗接種工作。

腺病毒疫苗市場促進因素與挑戰

腺病毒疫苗產業受到許多促進因素和挑戰的影響，包括技術進步、監管問題和經濟狀況。

推動腺病毒疫苗市場的因素是：

1.技術進步：市場是由基於病毒載體的疫苗和創新的遞送系統等技術所推動的。這些進展提高了疫苗的功效和安全性，並改善了疫苗的獲取，導致其廣泛接受。

2.提高公共衛生意識：人們對疫苗接種在預防感染疾病中作用的認知不斷提高，正在推動對腺病毒疫苗的需求。公共衛生宣傳活動和教育計劃推動了疫苗使用的增加。

3. 政府支持：政府對腺病毒疫苗的開發與銷售給予大力支持。這包括津貼、撥款和更快的核准流程，以縮短這些產品的上市時間。

4.全球疾病負擔：全球疾病負擔的增加，包括腺病毒引起的感染疾病，正在推動市場發展。預防疫情爆發並降低發病率和死亡率的需要導致對疫苗等預防措施的投資增加。

5. 大流行應對：在 COVID-19 大流行期間，腺病毒疫苗接種在全球大流行防範中的重要性已變得顯而易見。

腺病毒疫苗市場面臨的挑戰包括：

1. 監管障礙：由於世界各地存在複雜多元的法規環境，疫苗開發商面臨各種挑戰。國際經營的公司必須遵守許多法規。

2. 疫苗猶豫：儘管疫苗接種很重要，但這是相當大的挑戰之一。非洲正遭受嚴重的黃熱病流行，因為許多成年人在兒童時期沒有接種疫苗。

3.供應鏈限制：腺病毒疫苗的穩定供應仍然是一個障礙，特別是在新興國家。也有人避免接種疫苗，因為他們認為疫苗有害。

腺病毒疫苗市場的成長和開拓有許多促進因素和挑戰。雖然腺病毒疫苗市場是由這些技術突破和政府支持推動的，但它還需要解決阻礙大規模採用和供應的監管障礙和疫苗猶豫等問題。

腺病毒疫苗細分市場

本研究按類型、應用和地區對全球腺病毒疫苗進行了預測。

腺病毒疫苗市場的國家展望

活性化的研發活動、對疫苗可預防疾病的認知不斷提高以及全球應對新興感染疾病的努力正在推動腺病毒疫苗市場的成長。中國、德國、印度、日本和美國等主要市場在疫苗技術進步、生產和分銷方面取得了最新進展。

• 美國：腺病毒疫苗研究經費正在增加，特別是用於軍事和公共衛生應變方面。強生公司正在擴大產能以滿足國內和全球需求。
• 中國 中國今年的重點是腺病毒疫苗，特別是自 COVID-19 誕生以來。在政府的大力支持下，中國企業正在努力透過提高生產能力來提高疫苗的有效性，以提高疫苗在全國範圍內的使用率。
• 德國 德國研究機構處於腺病毒疫苗研究的前沿，正在進行合作以提高疫苗接種和有效性。我們也有興趣參與疫苗分配和擴大生產線的國際計劃。
• 印度 印度腺病毒疫苗的生產進展迅速。該國的法律規範涵蓋政府對當地疫苗開發商的資助，旨在成為全球疫苗供應的核心參與者。
• 日本 在日本，生產下一代腺病毒疫苗時越來越關注提高安全性和有效性。我們也關注國內健康需求和先進的製造技術，以確保快速製造和分銷。

常問問題

Q.1 腺病毒疫苗的市場規模有多大？

A1. 到2030年，全球腺病毒疫苗市場預計將達到14億美元。

Q.2 腺病毒疫苗市場的成長預測如何？

A2. 預計2024年至2030年全球腺病毒疫苗市場將以7.5%的複合年成長率成長。

Q.3 影響腺病毒疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要促進因素是癌症基因治療疫苗接種需求的激增以及製藥公司疫苗接種需求的激增。

Q4.市場的主要細分市場是：

A4. 腺病毒疫苗市場的未來看起來充滿希望，在研究/學術、實驗室和製藥/生物技術市場中存在著機會。

Q5.市場的主要企業是：

A5.主要企業如下：

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於 7 型疫苗價格實惠且能夠提供即時免疫力，因此在預測期內將出現高速成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於腺病毒感染的高流行和人口的持續成長，預計北美在預測期內將出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球腺病毒疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球腺病毒疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 全球腺病毒疫苗市場，依類型
  • 4型疫苗
  • 7型疫苗
• 全球腺病毒疫苗市場按應用
  • 研究和學術
  • 研究所
  • 製藥/生物技術

第4章 2018-2030年區域市場趨勢及預測分析

• 全球腺病毒疫苗市場（按地區）
• 北美腺病毒疫苗市場
• 歐洲腺病毒疫苗市場
• 亞太腺病毒疫苗市場
• 其他區域腺病毒疫苗市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球腺病毒疫苗市場按類型分類的成長機會
  • 全球腺病毒疫苗市場成長機會（按應用）
  • 全球腺病毒疫苗市場成長機會（按地區）
• 全球腺病毒疫苗市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球腺病毒疫苗市場產能擴張
  • 全球腺病毒疫苗市場的併購與合資
  • 認證和許可

第7章主要企業概況

• Novasep
• Charles River Laboratories
  • uniQure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Adenovirus Vaccine Trends and Forecast

The future of the global adenovirus vaccine market looks promising with opportunities in the research and academic, laboratories, and pharmaceutical & biotechnology markets. The global adenovirus vaccine market is expected to reach an estimated $1.4 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are the rapidly increasing need for vaccinations in cancer gene therapies and surge in vaccination demand from pharmaceutical companies.

Lucintel forecasts that type 7 vaccine is expected to witness higher growth over the forecast period due to its affordability and ability to instantly confer immunity.

North America is expected to witness highest growth over the forecast period due to due to the high prevalence of adenovirus infection and continuous population growth in the region.

Emerging Trends in the Adenovirus Vaccine Market

The market of adenovirus vaccine is subject to evolution through various emerging trends, which are thus key drivers of innovation and market growth. These trends mirror the ongoing discoveries in vaccine technology and the global fight against infectious diseases.

• Next-Generation Vaccines: The development of next-generation adenovirus vaccines seeks to improve efficacy, safety, and delivery. This can be seen in innovations such as vector-based vaccines and novel formulations designed to enhance immune responses while reducing side effects or other adverse reactions.
• Vaccine Manufacturing Expansion: There is a significant trend towards expanding worldwide vaccine manufacturing ability. To ensure a steady supply of adenovirus vaccines, especially during the time of the COVID-19 pandemic, countries are investing in advanced manufacturing facilities.
• Global Vaccine Distribution: Efforts are being made towards ensuring that adenovirus vaccines are available in low- and middle-income countries for equitable global vaccine distribution. Partnerships between governments, NGOs, and pharmaceutical companies are among this trend to achieve widespread access
• Regulatory Innovation: Regulatory authorities have implemented more flexible procedures for approving adenovirus vaccines at an accelerated rate. This reflects the public health crises' urgency and the necessity of hastening introduction of new drugs into the market by manufacturers.
• Collaboration in Research and Development: One of the major trends in the adenovirus vaccine market is increased collaboration between research institutions, biotech companies, and governments. Such partnerships have led to innovation and quickened the pace of vaccine development.

By driving technological innovation, expanding manufacturing capacities, and ensuring global vaccine access, these trends are reshaping the adenovirus vaccine market. The market is changing fast to meet emerging infectious diseases and public health needs.

Recent Developments in the Adenovirus Vaccine Market

Recent happenings in the adenovirus vaccine market highlight remarkable advancements in research, trading, and delivery due to global public health needs.

• Manufacturing Capacity Expansion: Major vaccine manufacturers are now increasing their production capacities so that they can be able to serve the ever-growing global demand for adenovirus vaccines. This expansion includes building new facilities and upgrading existing ones to increase output and ensure vaccine availability.
• Funding by Government and Support: Governments worldwide have committed huge sums of money towards the development of an adenovirus vaccine. Such funding may take various forms including grants, subsidies, or fastened regulatory approvals aimed at ensuring quick growth of vaccines.
• Collaborative Research Initiatives: The inclusion of partnerships with pharmaceutical companies has also enhanced innovation within the field of adenovirus vaccine development. These partnerships aim to enhance vaccines' efficiency, means of being administered as well as accessibility.
• Global Distribution Partnerships: Companies have established alliances that facilitate the provision of this vaccine globally, especially in low- to middle-income countries. These initiatives aim to bridge the equity gap among other things bringing vaccines closer to those who need them most.

These advancements are resulting in considerable improvements within the Adenovirus Vaccine industry, ensuring that vaccines are produced, developed, and delivered effectively to meet worldwide public health issues.

Strategic Growth Opportunities for Adenovirus Vaccine Market

Several strategic growth opportunities exist in the adenovirus vaccine market across different applications, impelled by technology advancements and heightened worldwide demand.

• Pediatric Vaccination Programs: Enhancing pediatric vaccination programs presents important avenues for growth. This entails developing adenovirus vaccines that are specific to children and can be included in national immunization programs thereby meeting a critical requirement about early childhood safety.
• Travel and Military Vaccination: Directing adenovirus vaccination at travelers and military personnel is one of the strategies that could lead to sustained growth. These cohorts have an elevated likelihood of contracting adenovirus, so there can be a formulation of vaccines catering specifically to them.
• Vaccine Combination Strategies: Merging adenovirus vaccines with other vaccines into single doses means opportunities for future growth. In resource-constrained environments particularly, this way of immunizing people simplifies schedules and increases coverage with further consequences.
• Pandemic Preparedness: The use of adenovirus vaccines for pandemic preparedness is poised for growth. Global health security demands the creation of vaccine stockpiles and their swift deployment during outbreaks.
• Personalized Vaccines: The development of adenovirus-based personalized vaccines tailored to individual genetic profiles represents an emerging source of business expansion. Vaccine efficacy is expected to increase through this strategy by matching immune responses to each individual's genetics.

These growth strategies are what are fueling the development and enlargement of the adenovirus vaccine market. By focusing on key applications in the market, there will be solutions to critical public health needs as well as global vaccination efforts.

Adenovirus Vaccine Market Driver and Challenges

The adenovirus vaccine industry is affected by a number of drivers and challenges, which include technological progress, regulatory concerns and economic conditions.

The factors responsible for driving the adenovirus vaccine market include:

1. Advancement in Technology : The market has been driven by technology including vaccines based on viral vectors and innovative delivery systems. These developments have improved vaccine efficacy and safety as well as access to them leading to their widespread acceptance.

2. Increased Public Awareness of Health: The growing awareness about the role of immunization in preventing infectious diseases is driving up demand for adenovirus vaccines. This rise in the use of vaccines has been boosted through public health campaigns and education programs.

3. Government Support: Notable support from governments has driven the development and distribution of adenovirus vaccines. This includes grants, subsidies and accelerated approval processes which speed up time-to-market for these products.

4. Global Burden Of Disease: The Market Is Driven By Increasing Global Burden Of Infectious Diseases Including Those Caused By Adenoviruses. Need to prevent outbreaks and reduce morbidity/mortality has led to greater investment in preventative measures such as vaccines.

5. Pandemic Response: The significance of adenoviral vaccination under global pandemic preparedness was revealed by COVID-19 outbreak that prompted more investments into developing vaccines with large stockpiles for quick response capacity buildup.

Challenges in the adenovirus vaccine market are:

1. Regulatory Hurdles: The problem of navigating through different complicated and varying regulatory environments in the world means that vaccine developers face a challenge. There are numerous rules which have to be followed by companies operating internationally.

2. Vaccine Hesitancy: Still, despite the importance of vaccination, it is one of the considerable challenges. This has seen many adults in Africa suffering from severe yellow fever outbreaks because they were never vaccinated as children.

3. Supply Chain Constraints: Steady supply of adenovirus vaccines, especially in developing countries remains an obstacle while new countries continue to demand for vaccines. Some people have been avoiding vaccinations because they believe that such drugs are harmful.

There are several driving factors and challenges that shape the adenovirus vaccine market on its way to growth and development. The market is being driven ahead by these technological breakthroughs as well as government assistance but there has to be a solution for issues like regulatory hurdles and vaccine hesitancy which hinderize uptake and availability of vaccines on large scale.

List of Adenovirus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adenovirus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adenovirus vaccine companies profiled in this report include-

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Adenovirus Vaccine by Segment

The study includes a forecast for the global adenovirus vaccine by type, application, and region.

Adenovirus Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Type 4 Vaccine
• Type 7 Vaccine

Adenovirus Vaccine Market by Application [Analysis by Value from 2018 to 2030]:

• Research and Academic
• Laboratories
• Pharmaceutical & Biotechnology

Adenovirus Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Adenovirus Vaccine Market

Increasing research and development activities, increasing awareness of vaccine-preventable diseases, and global efforts to address emerging infectious diseases are driving the growth of the adenovirus vaccine market. In terms of vaccine technology advancement, production, and distribution there have been recent developments in key markets such as those in China, Germany, India, Japan, and The United States.

• United States: There has been increased adenovirus vaccine research funding, particularly for the military and public health response. New vaccine candidates have received accelerated approvals from FDA while Johnson & Johnson is expanding its production capacity to satisfy domestic demand as well as global ones.
• China: This year China has focused on adenovirus vaccines especially after COVID-19 came into being. Chinese firms are working on making vaccines more effective by improving their manufacturing capacity with considerable government backing that promotes availability across the country.
• Germany: Institutions in Germany have been at the forefront of adenovirus vaccine studies where collaborative research is being conducted to advance ways towards bettering vaccination delivery and efficacy. The country is also interested in expanding production lines besides joining international initiatives on the distribution of vaccines.
• India: India is progressing swiftly in the production of adenovirus vaccines on account of its huge manufacturing capacity. The country's regulatory framework covers government funding for local vaccine developers, which aims to position it as a central player in global vaccine supplies.
• Japan: In Japan, more attention is given to safety and efficacy improvements when making future-generation adenovirus vaccines. It also focuses on advanced manufacturing technologies to ensure quick production and distribution emphasizing domestic health needs.

Features of the Global Adenovirus Vaccine Market

Market Size Estimates: Adenovirus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Adenovirus vaccine market size by type, application, and region in terms of value ($B).

Regional Analysis: Adenovirus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the adenovirus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adenovirus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the adenovirus vaccine market size?

Answer: The global adenovirus vaccine market is expected to reach an estimated $1.4 billion by 2030.

Q.2 What is the growth forecast for adenovirus vaccine market?

Answer: The global adenovirus vaccine market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the adenovirus vaccine market?

Answer: The major drivers for this market are the rapidly increasing need for vaccinations in cancer gene therapies and surge in vaccination demand from pharmaceutical companies.

Q4. What are the major segments for adenovirus vaccine market?

Answer: The future of the adenovirus vaccine market looks promising with opportunities in the research and academic, laboratories, and pharmaceutical & biotechnology markets.

Q5. Who are the key adenovirus vaccine market companies?

Answer: Some of the key adenovirus vaccine companies are as follows:

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Q6. Which adenovirus vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that type 7 vaccine is expected to witness higher growth over the forecast period due to its affordability and ability to instantly confer immunity.

Q7. In adenovirus vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to due to the high prevalence of adenovirus infection and continuous population growth in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the adenovirus vaccine market by type (type 4 vaccine and type 7 vaccine), application (research and academic, laboratories, and pharmaceutical & biotechnology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Adenovirus Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Adenovirus Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Adenovirus Vaccine Market by Type
  • 3.3.1: Type 4 Vaccine
  • 3.3.2: Type 7 Vaccine
• 3.4: Global Adenovirus Vaccine Market by Application
  • 3.4.1: Research and Academic
  • 3.4.2: Laboratories
  • 3.4.3: Pharmaceutical & Biotechnology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Adenovirus Vaccine Market by Region
• 4.2: North American Adenovirus Vaccine Market
  • 4.2.1: North American Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine 4.2.2: North American Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.3: European Adenovirus Vaccine Market
  • 4.3.1: European Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.3.2: European Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.4: APAC Adenovirus Vaccine Market
  • 4.4.1: APAC Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.4.2: APAC Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.5: ROW Adenovirus Vaccine Market
  • 4.5.1: ROW Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.5.2: ROW Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Adenovirus Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Adenovirus Vaccine Market by Application
  • 6.1.3: Growth Opportunities for the Global Adenovirus Vaccine Market by Region
• 6.2: Emerging Trends in the Global Adenovirus Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Adenovirus Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adenovirus Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novasep
• 7.2: Charles River Laboratories
  • 7.1.1: uniQure
• 7.4: Waisman Biomanufacturing
• 7.5: Creative-Biogene
• 7.6: Aldevron
• 7.7: Addgene
• 7.8: Thermo Fisher Scientific
• 7.9: Fujifilm Corporation
• 7.10: Spark Therapeutics